Corrections

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e5129 (Published 26 July 2012) Cite this as: BMJ 2012;345:e5129

There is an error in this Research paper by Karagiannis and colleagues (BMJ 2012;344:e1369, doi:10.1136/bmj.e1369) and in our previously published correction (BMJ 2012;345:e4959). In the final paragraph of the section “Glycaemic efficacy,” the risk ratio in favour of GLP-1 agonists should have been 1.82, 95% confidence interval 1.50 to 2.21; I2=0% [not “1.33, 1.09 to 1.63; I2=26%” as published in the original paper, or “1.82, 95% confidence interval 1.50 to 2.21; I2=26%” as published in the previous correction].

Notes

Cite this as: BMJ 2012;345:e5129

View Abstract